Methotrexate showed efficacy both in Crohn’s disease and ulcerative colitis, predictors of surgery were identified in patients initially treated with methotrexate monotherapy.

Mengyao Wang¹, Jingwen Zhao¹, Heran Wang¹, Changqing Zheng¹, Bing Chang²* and Lixuan Sang¹*

¹Department of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang, China, ²Department of Gastroenterology, The First Affiliated Hospital of China Medical University, Shenyang, China

Objective: This study aimed to evaluate methotrexate efficacy in patients with Crohn’s disease (CD) and ulcerative colitis (UC), and identify predictors of surgery for patients who were initially treated with methotrexate monotherapy.

Design: We performed a retrospective analysis of 34,860 patients with inflammatory bowel disease (IBD) in the IBD Bioresource (United Kingdom) prior to 9 November 2021. Logistic regression was used to identify factors associated with methotrexate efficacy. The data were randomly stratified into training and testing sets (7:3). Nomograms were developed based on Cox regression analysis outcomes. The predictive accuracy and discriminative ability were determined using the concordance index (C-index) and calibration curves.

Results: Overall, 1,042 patients (CD: 791, UC: 251) were included. Independent factors associated with effective methotrexate monotherapy were younger age at diagnosis, latest therapy period, exclusive upper gastrointestinal tract disease (for CD), and longer duration between diagnosis and methotrexate initiation (for UC). For CD, predictors in the nomogram were gender, treatment era, tolerance, lesion site, perianal involvement, disease behaviour, and biologics requirements (C-index: 0.711 and 0.732 for training and validation cohorts, respectively). For UC, the factors were age at diagnosis and sex (C-index: 0.784 and 0.690 for training and validation cohorts, respectively). Calibration curves
demonstrated good agreement between predictions and actual observations.

KEYWORDS
inflammatory bowel disease, methotrexate monotherapy, prognostic analysis, Crohn’s disease, ulcerative colitis

Introduction

Inflammatory bowel diseases (IBD), including ulcerative colitis (UC), Crohn’s disease (CD), and IBD-unclassified (IBDU), are disorders of chronic intestinal inflammation characterised by repeated aggravation and remission. Its increasing incidence has caused a huge economic burden on patients and country’s healthcare systems (Kaplan, 2015; Rosen et al., 2015; Ng et al., 2017; Coward et al., 2019). Conventional immunomodulators, including methotrexate and thiopurines, have been the mainstay of IBD treatment for decades, especially to maintain remission in steroid-dependent or steroid-refractory patients (Sales-Campos et al., 2015; Torres et al., 2020a; Ran et al., 2021; Raine et al., 2022).

Methotrexate, which was initially developed in 1948 for the treatment of leukemia (Gabbani et al., 2016), has been clinically used for other diseases, including IBD, psoriasis, and rheumatoid arthritis (Tung and Maibach, 1990; Rajitha et al., 2017). Due to hepatotoxicity and gastrointestinal symptoms, patients treated with methotrexate should routinely undergo a full blood count and liver and pancreatic function tests during the treatment period (Cervoni et al., 2020; Vasudevan et al., 2020; Ran et al., 2021). In recent years, with the emergence of biological agents and concerns regarding their adverse effects, the application of methotrexate in IBD has been questioned.

The European Crohn’s and Colitis Organisation (ECCO) Guidelines on Therapeutics for patients with CD recommend parenteral administration of methotrexate for the maintenance of remission in steroid-dependent patients (Torres et al., 2020b). A multicentre randomised control trial (RCT) (Feagan et al., 1995) study of 141 patients with chronically active CD found that after 16 weeks, 37 patients (39.4%) in the methotrexate group were in clinical remission compared with 9 patients (19.1%) in clinical remission in the placebo group \( p = 0.025 \), moreover the methotrexate group had received less prednisone than the placebo group \( p = 0.025 \). However, there is not enough evidence supporting methotrexate for the maintenance of remission in UC patients. A French study (Carbonnel et al., 2016) assessed the efficacy of methotrexate in inducing UC steroid-free remission, after 16 weeks, methotrexate group was not superior to placebo with regards to induction of steroid-free remission \( p = 0.15 \). Moreover, more patients in the placebo group experienced continued UC disease activity that required withdrawal from the aforementioned study. Further studies are needed to determine the effectiveness of methotrexate in UC maintenance therapy.

IBD has become a global problem characterised by a lifelong relapsing-remitting course, which diminishes the quality of life of patients and increases the consumption of healthcare resources. Thus, long-term efficacy is an important aspect of IBD treatment. A prior meta-analysis of 44 cohort studies suggested that for diagnosed patients, the 1-, 5- and 10- year surgery risk for patients with UC (colectomy with or without an ileal pouch–anal anastomosis) was 2.8%, 7.0%, and 9.6%, respectively, and for patients with CD (intestinal resection) was 12.3%, 18.0%, and 26.2%, respectively (Tsai et al., 2021). Because of the overall burden of IBD and its multifactorial aetiology, efforts should be made to improve the medical management of these inflammatory conditions. Identifying factors associated with surgery can help optimise the treatment plan.

Methods

Here, we analyses the effectiveness of methotrexate in IBD treatment using the United Kingdom IBD BioResource (www.ibdbioresource.nihr.ac.uk), which launched in 2016 as part of the United Kingdom National Institute for Health Research BioResource (Parkes, 2019). The database contained a large number of patients whose information were ascertained at enrolment and updated annually, including demographic, clinical characteristics, and treatment informations. All patients signed consent forms allowing their information to be used by investigators. To obtain these data, a data application was submitted to IBD BioResource.

Patient population

A total of 34,860 patients in over 100 hospitals in the United Kingdom signed up before the data lock on 9 November 2021.

The following patients were excluded: 1) those whose basic information on IBD or treatment response was missing; 2) those who underwent surgery in the same year of methotrexate initiation; 3) those who started or were on biological therapy in the year of methotrexate initiation; and 4) those for whom we could not determine whether biological therapy or surgery overlapped the period of methotrexate monotherapy. Patients with UC who underwent colectomy prior to methotrexate initiation were also excluded. Surgery is common in CD progression; therefore, those who underwent surgery before
methotrexate initiation were not excluded. IBDU was classified as UC in our study, since we were able to find UC-related information of IBDU patients in the database.

**Treatment effectiveness**

Effectiveness was evaluated by asking the question, “Did methotrexate work?” Effectiveness was defined as answering “yes” and avoiding escalation to alternative (biologics and/or surgical) treatment during the methotrexate treatment. We also discussed the treatment duration between the initiation of methotrexate and escalation to biologics or surgery (whichever occurred first), which also reflected the effectiveness of methotrexate.

**Definitions in study**

The diagnosis of IBD was made based on radiographic, endoscopic, histologic criteria, or physician judgment. For CD, disease location were classified as “ileal” (L1), “colonic” (L2), “ileo-colonic” (L3), “exclusive upper gastrointestinal tract (GI) Crohn’s” (L4); disease behaviour were classified as “stenosing”, “internal penetrating” and “inflammatory and others”; internal penetrating disease was defined if patients had evidence of entero-enteric or entero-vesicular fistulae, intra-abdominal abscesses or intestinal perforation; perianal involvement including tags, fissures, ulcers, perianal abscess, simple fistula (single fistula, little clinical problem), complex fistula (more than one or branching or recto-vaginal or major problem); surgery including colectomy, ileal or jejunal resection and the treatment of complications such as drainage of perianal abscess, perianal fistula repairment. For UC, disease location were divided into “proctitis” (E1), “left sided” (E2), “extensive” (E3); surgery referred colectomy. Smoking history included current and past smoking. In Cox regression, biologics requirement referred to that patients requiring biologics after methotrexate initiation and before surgery; glucocorticoid requirement referred to that patients receiving intravenous glucocorticoids before or after methotrexate initiation, but before surgery.

**Statistical analysis**

Continuous variables are presented as mean ± SD or median ± interquartile range (IQR), while categorical variables are presented as percentages or proportions. Continuous variables were analysed using Student’s t-tests or paired t-tests, as appropriate, while categorical variables were analysed using the chi-square or Fisher’s exact test. The Cochran-Mantel-Haenszel (CMH) test was applied to compare effectiveness of methotrexate between UC and CD.
using stratified treatment initiation periods every 5 years. Multivariable logistic regression was performed to compare methotrexate effectiveness between patients with UC and CD, adjusting for age at diagnosis, gender, smoking history, treatment era, and time interval from diagnosis to methotrexate initiation. Next, univariate and multivariable logistic regression analyses were used to identify independent risk factors of methotrexate monotherapy effectiveness within UC and CD using the same covariates as above, but also including disease location (variables with \( p < 0.2 \) were included in multivariable regression). The CD and UC cohorts were randomly divided into training and validation cohorts at a ratio of 7:3. Univariate Cox regression was then used to screen for variables that were significantly correlated with surgery occurrence in the training group with the same covariates as above, but also included biologics, glucocorticoid treatment, and previous surgery. Predictors with \( p < 0.2 \) were fed into multivariable Cox regression model. Backward stepwise selection based on Akaike’s information criterion (AIC) was used to further eliminate redundant variables. The performance of the nomogram was evaluated using the concordance index (C-index) and a calibration curve in both the training and validation cohorts. A larger C-index indicates more accurate prognostic stratification. A \( p \)-value threshold of \(< 0.05 \) was considered statistically significant in the adjusted models. All statistical analyses were performed using the R software (version 4.1.0).

## Results

### Patient population

Of the 34,860 participants in the IBD BioResource at the data lock, 2876 (8.25%) had been treated with methotrexate (76.7%...
with CD, 21.7% with UC, and 1.6% with IBDU), either as monotherapy or combined with biologics. As shown in Figure 1, 1042 participants met the criteria for assessment of the effectiveness of methotrexate monotherapy [791 CD and 251 UC (including 15 IBDU cases)]. The baseline patient characteristics are presented in Table 1. The median age at CD and UC diagnosis was 30 and 38 years, respectively. Nausea was the most common adverse reaction in both patients with CD and UC. Patients who could not tolerate methotrexate were prone to have a nauseous reaction (CD: 30.2% vs. 10.1%, \( p < 0.001 \); UC: 31.8% vs. 6.1%, \( p < 0.001 \)).

Among the 1042 patients, 181 (17.4%) were unable to tolerate and had to stop methotrexate. The median duration of methotrexate treatment was 2 years (IQR: <1–6 years) for patients with CD and 3 years (IQR: 1–7 years) for patients with UC. The median time from diagnosis to methotrexate

\[ \text{FIGURE 2} \]

(A) Time interval (years) between CD or UC diagnosis and methotrexate monotherapy; (B) Odds ratio (OR) of methotrexate monotherapy being effective in UC vs. CD stratified by therapy period. The horizontal coordinates are OR values, blue boxes indicate OR values for every era, and black solid lines indicate 95% confidence intervals (CI) for OR values; (C) The Kaplan-Meier curve shows the duration of methotrexate treatment in patients in whom methotrexate monotherapy was considered effective; (D) The Kaplan-Meier curve shows the duration of effective methotrexate monotherapy without requirement for treatment escalation (\( p < 0.0001 \) for log-rank test). (CD, Crohn’s disease; UC, ulcerative colitis).
initiation was 5 years in both patients with CD and UC (Figure 2A). A total of 486 (61.44%) patients with CD and 106 (42.2%) with UC received biologics after methotrexate monotherapy.

**Effectiveness of methotrexate monotherapy**

Overall, 28.9% (301/1042) cases were regarded as effective, without escalation to biologics or surgery during treatment. Methotrexate monotherapy was effective in 35.5% of patients with UC (94/251) and a lower proportion of patients with CD (26.7%; 211/791, \( p = 0.001 \)). In methotrexate-tolerant group, it was effective in 39.3% of patients with UC and 32.8% of patients with CD (\( p = 0.074 \)).

According to the CMH test stratified by the treatment initiation era (every 5 years), methotrexate appeared to be more effective in UC than in CD (odds ratio [OR]: 1.429, 95% confidence interval [CI]: 1.050–1.944, \( p = 0.023 \)). The test of homogeneity of ORs indicated that there was no heterogeneity in the OR values of each therapy area (\( p = 0.237 \)). We used the forest map to display the OR values of each era, and the results were meaningful only for the 2006–2010 period (Figure 2B). There were no statistically significant differences between the treatment effectiveness of CD and UC in most eras.

Among patients with CD, the effective ratio of methotrexate monotherapy increased, whereas patients with UC showed a decreasing trend, except in the period after 2016 (Supplementary Figure S1). We then incorporated the treatment era along with other possible confounding factors into the multivariable logistic regression analysis (Table 2). The results demonstrated that there were no statistically significant differences in methotrexate effectiveness between CD and UC (OR: 1.359, 95% CI: 0.988–1.863, \( p = 0.058 \)).

**Clinical characteristics and methotrexate monotherapy effectiveness**

For patients with CD, multivariable analysis showed that after controlling for confounding factors, methotrexate monotherapy appeared to be more effective in older patients (OR: 1.028 per year; 95% CI: 1.017–1.040, \( p < 0.001 \)). In addition, the more recent the treatment, the better the treatment outcomes with methotrexate (OR: 1.363, 95% CI: 1.152–1.623, \( p = 0.001 \)). Patients with exclusive upper gastrointestinal tract disease were considered to receive more effective treatment than those with ileo-colon involvement (OR: 3.797, 95% CI: 0.973–14.855, \( p = 0.049 \)). Univariate logistic regression showed statistical significance for gender, disease behaviour, and perianal involvement; however, no statistical significance was obtained with multivariable logistic regression. No correlation was found between smoking history and the time from diagnosis to methotrexate initiation (Table 3).

For patients with UC, univariate logistic regression showed statistical significance for age, gender, smoking history, treatment eras, and time from diagnosis to methotrexate initiation; after controlling for confounding factors, the multivariable analysis only demonstrated statistical significance for the time interval from diagnosis to methotrexate initiation (Table 3).

**Duration of effective treatment**

For patients in whom methotrexate monotherapy was deemed effective (301), 68.8% (207) were still treated with methotrexate at the time of data lock. The Kaplan-Meier curve illustrated that over
50% of this group was still on methotrexate at data lock in both the CD and UC groups. (Figure 2C, $p = 0.56$, log-rank test).

Of the patients treated with methotrexate monotherapy, 532 (51.1%) required treatment escalation after a median time of 5 years in the CD group, 11 years in the UC group, and earlier escalation in the CD group. (Figure 2D, $p < 0.0001$ for the log-rank test).

50% of this group was still on methotrexate at data lock in both the CD and UC groups. (Figure 2C, $p = 0.56$, log-rank test).

Of the patients treated with methotrexate monotherapy, 532 (51.1%) required treatment escalation after a median time of 5 years in the CD group, 11 years in the UC group, and earlier escalation in the CD group. (Figure 2D, $p < 0.0001$ for the log-rank test).

Of the patients treated with methotrexate monotherapy, at 1 and 3 years, 78.3% and 55.9% of patients with CD and 85.7% and 69.5% of patients with UC, respectively, remained on methotrexate and did not require treatment escalation to biologics or surgery (Supplementary Table S1).

### TABLE 3

| Factor                  | CD                | UC                |
|-------------------------|-------------------|-------------------|
|                         | Univariable       | Multivariable     |
|                         | OR and 95% CI     | p Value           | OR and 95% CI | p Value |
| Age at diagnosis        | 1.036 (1.025–1.047) | <0.001            | 1.013 (0.995–1.033) | 0.168 |
|                         | 1.028 (1.017–1.040) |                  | (0.995–1.033) | (0.989–1.029) |
| Gender                  | Female            | Male              |
|                         | 1.384 (1.002–1.922) | 1.293 (0.919–1.829) | 1.477 (0.881–2.486) | 0.140 |
|                         | (0.909–1.829)     |                   |                  |           |
| Smoking history         | Yes               | No                |
|                         | 0.981 (0.709–1.353) | 1.142 (0.970–1.322) | 1.142 (0.942–1.858) | 0.076 |
|                         |                   |                   | (0.952–1.737) | (0.848–2.625) |
| Therapy period          | 1.550 (1.318–1.833) | 1.363 (1.152–1.623) | 1.224 (0.994–1.626) | 0.152 |
| CD location             | Ileal             | Colonic           |
|                         | 1.454 (0.988–2.146) | 1.487 (1.008–2.216) | 3.587 (0.970–13.275) | 1.213 |
|                         | (0.995–2.146)     | (0.806–1.883)     | (0.973–14.855) | (0.923–1.614) |
| UC location             | Proctitis (E1)    | Left sided (E2)  |
|                         | 3.587 (0.970–13.275) | 0.825 (0.479–1.421) | 1.142 (0.436–2.892) | 0.781 |
|                         | (0.973–14.855)    |                   | (0.479–1.421) |           |
| Behaviour               | Internal penetrating | Inflammatory and other | 0.665 (0.457–0.955) | 0.540 |
|                         | 0.431 (0.210–0.813) | Reference         | (0.364–0.787) | (0.364–0.787) |
|                         | (0.210–0.813)     | Reference         | (0.511–1.178) | (0.511–1.178) |
|                         | 0.049 (0.973–14.855) | Reference         | Reference | Reference |
|                         |                   |                   |                   |           |
| Time from diagnosis to  | 1.005 (0.990–1.020) | 1.041 (1.011–1.071) | 0.006 (1.001–1.002) | 0.002 |
| methotrexate initiation | 0.482 (0.990–1.020) | 1.041 (1.011–1.071) | 1.056 (1.021–1.092) |           |

Significant $p$ values shown in bold; CD, Crohn’s disease; UC, ulcerative colitis; OR, odds ratio; CI, confidence interval; GI, gastrointestinal tract.
Development and validation of prognostic nomograms for predicting surgery in CD patients treated initially with methotrexate monotherapy

In total, 382/791 patients with CD (48.3%) treated with methotrexate monotherapy underwent surgery, 202/791 (25.5%) patients underwent at least two surgeries, and 198/791 (25.0%) underwent surgery after methotrexate initiation. The rates of 1-, 3- and 5-year no-surgery were 93.4%, 86.4% and 82.1%, respectively. A total of 159 patients with CD could not tolerate treatment, and their treatment time interval to surgery was modestly shorter than that of the 632 methotrexate-tolerant patients (Figure 3; \( p = 0.029 \) for log-rank test).

Surgery occurrence and time interval in the treatment process are important indicators of treatment effectiveness. A total of 791 patients with CD were randomly divided into training and validation cohorts at a ratio of 7:3. There was no statistically significant difference between the two groups (Supplementary Table S2). Finally, the variables included in the nomogram were sex, disease location, disease behaviour, perianal involvement, tolerance, treatment period, and biological requirements based on outcomes of Cox regression (Table 4; Figure 4). The C-index was 0.711 [0.664–0.758] in the training cohort and 0.732 [0.661–0.803] in the validation cohort. As shown in Figure 5, the calibration curves showed good agreement between predictions of 1-, 3-, and 5-year of surgery occurrence and the actual observations in both the training and validation cohorts.

Establishment and validation of prognostic nomograms for predicting surgery in UC patients treated initially with methotrexate monotherapy

Of the 251 patients with UC, 15 (6.0%) underwent colectomy. The indications for colectomy included acute severe colitis in 6 patients (40%), chronic continuous colitis in 6 patients (40%), dysplasia in 1 patient (6.7%), and undocumented reasons in 2 patients. The 1-, 3- and 5-year no-surgery rates were 97.6%, 96.0%, and 95.1%, respectively. Overall, 4/22 (18.2%) patients who were unable to tolerate methotrexate required colectomy, compared with 11/229 (4.8%) patients who could tolerate methotrexate. Time to colectomy was shorter in individuals unable to tolerate methotrexate than in those able to tolerate methotrexate (Figure 6, \( p = 0.013 \) for log-rank test).

251 UC patients with were randomly divided into training and validation cohorts at a ratio of 7:3. There was no statistically significant difference between the two groups (Supplementary Table S3). All factors were analysed using univariate regression analysis to identify potential risk variables. Potential risk factors (\( p < 0.2 \) in univariate regression analysis) were selected for stepwise regression analysis with backward selection procession by AIC. Finally, the variables included in the nomogram were sex and age at UC diagnosis (Table 4; Figure 7). The C-index was 0.784 [0.600–0.968] and 0.690 [0.502–0.878] in the training and validation cohorts, respectively. As shown in Figure 8, the calibration curves showed good agreement between the predictions of surgery occurrence and the actual observations in both the training and validation cohorts.

Discussion

Through this retrospective study that enrolled 791 patients with CD and 251 with UC, we report the first large-scale study assessing the clinical characteristics and patient-level outcomes of patients with CD and UC treated with methotrexate, using the IBD BioResource. Currently, non-biological treatments remain valuable approaches for patients with IBD; however, their long-term outcome data remain sparse. In our study, 8.25% of patients had been treated with methotrexate, either as a monotherapy or combination therapy, and methotrexate provided an effective long-term treatment for 35.5% of patients with UC and 26.7% with CD without escalation therapy. A multicentre retrospective study in the Netherlands suggested that 86%, 63%, 47%, and 20% of patients with CD who were treated with methotrexate monotherapy obtained clinical benefits at 6, 12, 24, and 60 months, respectively (Seinen et al., 2013). Our study also evaluated the tolerability and safety of methotrexate; of the 1042 patients, 181 (17.4%) patients were unable to tolerate and had to stop methotrexate, consistent with previous studies (Herfarth et al., 2016). Nausea was the most common adverse
TABLE 4 Univariate and multivariable Cox regression for determining factors affecting surgery in patients with CD and UC treated with methotrexate monotherapy.

| Factor                          | CD                          | Multivariable (backward stepwise) | UC                          | Multivariable (backward stepwise) |
|--------------------------------|-----------------------------|-----------------------------------|-----------------------------|-----------------------------------|
|                                | Univariable                 | Multivariable                     | Univariable                 | Multivariable                     |
|                                | OR and 95% CI               | p Value                           | OR and 95% CI               | p Value                           |
| Age at diagnosis               | 0.981 (0.969–0.992)         | <0.001                            | 0.940 (0.885–0.998)         | 0.042                             |
| Gender                         | Female 0.681 (0.494–0.938)  | 0.019                             | 0.710 (0.512–0.985)         | 0.040                             |
|                                | Male Reference              | Reference                          | Reference                    | Reference                          |
| Smoking history                | Yes 0.924 (0.666–1.283)     | 0.638                             | 0.555 (0.112–2.759)         | 0.472                             |
|                                | No Reference                | Reference                          | Reference                    | Reference                          |
| Therapy period                 | 0.769 (0.663–0.892)         | <0.001                            | 0.810 (0.695–0.943)         | 0.001                             |
| Disease location               | Ileal 0.740 (0.609–1.075)   | 0.144                             | 0.935 (0.624–1.401)         | 0.745                             |
|                                | Colonic 0.418 (0.271–0.645) | <0.001                            | 0.537 (0.342–0.841)         | 0.007                             |
|                                | Exclusive upper Gl Crohn’s | 1.001 (0.315–3.181)               | 0.998 (0.462–4.936)         | <0.001 (0–Infinity)               |
|                                | Ileo-colonic                | Reference                          | Reference                    | 0.999                             |
| Behaviour                      | Sternoing 2.137 (1.495–3.053) | <0.001                            | 1.843 (1.272–2.671)         | 0.001                             |
|                                | Internal penetrating 3.815 (2.453–5.933) | <0.001   | 2.775 (1.734–4.441)         | <0.001                             |
|                                | Inflammatory and other      | Reference                          | Reference                    | Reference                          |
| Perianal involvement           | Yes 1.923 (1.391–2.659)     | <0.001                            | 1.609 (1.125–2.299)         | 0.009                             |
|                                | No Reference                | Reference                          | Reference                    | Reference                          |
| Time from diagnosis to         | 0.991 (0.974–1.008)         | 0.074                             | 1.000 (0.918–1.088)         | 0.004                             |
| methotrexate initiation        | Tolerate                    | Reference                          | Reference                    | Reference                          |
|                                | Yes 0.716 (0.497–1.032)     | 0.560                             | 0.238 (0.048–1.79)          | 0.079                             |
|                                | No Reference                | Reference                          | Reference                    | Reference                          |
| Previous surgery               | Yes 1.403 (1.011–1.947)     | 0.043                             | Reference                    | Reference                          |
| Biologics requirement          | Yes 0.790 (0.572–1.090)     | 0.151                             | 0.004 (0.340–5.438)         | 0.664                             |
| Glucocorticoid requirement     | Yes 0.459                   | Reference                          | Reference                    | 0.998                             |

(Continued on following page)
reaction, especially in the intolerance group; hepatotoxicity and fatigue were also observed without fatal adverse reactions. A retrospective study published in 2022 reported that methotrexate-induced nausea was noted in 34% of paediatric patients with IBD (Mehta et al., 2022). In our study, over 50% of methotrexate-effective patients were still on treatment at data lock in the two groups. Methotrexate treatment is relatively safe, with a low rate of adverse reactions and no fatal adverse reactions.

In this study, methotrexate appeared effective in both CD and UC, with no difference, consistent with a previous cohort study (Wahed et al., 2009). The ECCO Guidelines recommend methotrexate for the maintenance of remission in patients with steroid-dependent CD, however, for patients with UC, no clear application guidelines are available. In our study, the CMH test was more effective in UC than in CD; we also found evidence of increased methotrexate effectiveness in CD and a decreasing trend in UC (Supplementary Figure S1). Multivariable logistic regression analysis showed no statistical significance between CD and UC ($p = 0.058$) in the adjusted models. By further comparison, methotrexate had a better effect on patients with UC than on those with CD in avoiding escalation treatment (Figure 2D). Surgical risk factors include perianal involvement, internal penetration, and stenosis. After excluding these patients, the Kaplan-Meier curve showed that the protective effect of methotrexate on CD was significantly increased, and the gap between CD and UC was decreased (Supplementary Figure S2 vs. Figure 2D). We excluded patients with UC who had undergone colectomy, which resulted in a bias for milder disease among the participants. Those who had undergone CD-related surgery were analysed, showing a bias in disease severity. Our study is based in a single region of the United Kingdom with a limited number of cases, and endoscopy estimation was not available. In the future, prospective RCTs are needed to compare the efficacy of methotrexate in CD and UC.

In Table 4 (Continued), we present the univariate and multivariable Cox regression for determining factors affecting surgery in patients with CD and UC treated with methotrexate monotherapy.

| Factor          | CD                  | UC                  |
|-----------------|---------------------|---------------------|
|                 | Univariable         | Multivariable (backward stepwise) | Univariable | Multivariable (backward stepwise) |
| OR and 95% CI   | $p$ Value           | OR and 95% CI       | $p$ Value   | OR and 95% CI       | $p$ Value   |
| Yes             | 1.191 (0.750–1.892) | <0.001 (0–Infinity) | Reference   | Reference           |
| No              | Reference           | Reference           |             |                     |

Significant $p$ values shown in bold; CD, Crohn’s disease; UC, ulcerative colitis; OR, odds ratio; CI, confidence interval; GI, gastrointestinal tract.
In the current study, over 50% of the patients in whom treatment was deemed effective were still on methotrexate at the data lock, with a median treatment duration of 5 (CD) and 11 (UC) years. It seems that methotrexate is adhered to for prolonged periods (and effective), despite well-documented concerns about increased risk of hepatotoxicity and long-term blood cell reduction.

Our analysis identified specific patient subgroups that were most likely to respond to methotrexate. These included older patients treated in the recent period with exclusive upper GI disease for CD. Older patients with better outcomes may have a milder course (Charpentier et al., 2014). Although the \( p \) value of upper GI disease was less than 0.05, the OR value contains 1, and previous studies have shown that upper GI disease \( (p = 0.042) \) was significantly associated with an increased risk of surgical recurrence (Frolkis et al., 2013), larger trials are needed to confirm this. For UC, in multivariable analysis, the time interval from diagnosis to methotrexate initiation was an independent factor associated with effectiveness of treatment \((\text{OR}: 1.056, 95\% \text{ CI}: 1.021–1.092 \text{ per year})\). After further analysis, we found that the methotrexate-tolerant group had a longer median time interval between diagnosis and methotrexate initiation than the methotrexate-intolerant group (5 years vs. 3 years).

**FIGURE 5**
Calibration curve of nomogram for predicting no surgery occurrence at (A) 1-, (C) 3-, and (E) 5-years in the training cohort, and at (B) 1-, (D) 3-, and (F) 5-years in the validation cohort. The actual proportion is plotted on the Y-axis and the nomogram-predicted probability is plotted on the X-axis. (CD, Crohn’s disease).
We further analysed the patients’ clinical characteristics and occurrence of surgery. Identification of patients at the highest risk of disease progression, who have the greatest chance of benefiting from early initiation of effective therapy, is an aspirational goal. For CD, 202/791 (25.5%) patients underwent at least two surgeries, and 198/791 (25.0%) underwent surgery after methotrexate initiation. We identified factors associated with surgery occurrence through univariate Cox regression as follows: age at diagnosis, gender, therapy era, disease location, perianal involvement, disease behaviour, tolerance, previous surgery history, biologics, and glucocorticoid treatment. For UC, 15/251 (6.0%) patients required colectomy after methotrexate treatment. Univariate Cox regression analysis revealed that the age at diagnosis, sex, and tolerance were significantly associated with early surgery. We then performed stepwise regression based on AIC to select factors into the final prognostic model so that clinicians could identify patients at higher risk of surgery and implement more aggressive medical management as required.

Surgery is generally considered as a last-resort treatment for IBD. A review published in 2013 suggested that the 1- and 5- year surgery risk after diagnosis of UC was 4.9% and 11.6%, respectively, and that of CD was 16.3% and 33.3%, respectively (Samuel et al., 2013a). For patients diagnosed in the 21st century, the cumulative 5- year risk of surgery was 7.0% for UC and 17.8% for CD, substantially lower than the previous review (Tsai et al., 2021). In our study, for CD, the rates of 1- and 5- year surgery occurrence were 6.6% and 17.9%, respectively. For UC, the rates of 1- and 5- year surgery occurrence were 2.4% and 4.9%, respectively. In our study, the surgery rates were lower than those reported, reflecting the effectiveness of methotrexate. Although the number of surgeries
has been decreasing, it still poses a huge burden to patients. One of the biggest challenges clinicians face today is predicting which patients are prone to surgery requirements. Those at the highest risk of surgery may benefit the most from early surgery.

As the nomograms show, female is a predictor of a lower risk of surgical treatment for both, patients with CD and UC. A consensus has been reached that male sex may be associated with a greater risk of growth impairment, and growth impairment diagnosis predicts an increased risk of bowel surgery (Ricciuto et al., 2021). A previous study of UC showed that male sex was significantly associated with colectomy risk (Samuel et al., 2013b; Macaluso et al., 2019). Jia-Yin et al. (Yao et al., 2020) developed a nomogram to predict 1-year surgery risk in patients with CD without the sex variable. The people we enrolled were all from the United Kingdom, therefore, regional bias should be accounted for.

Smoking cessation is generally advised for patients with CD. However, in our study, smoking history was not a predictor of surgery occurrence in either UC or CD. Current smokers had a reduced risk of UC (odds ratio [OR]: 0.61) and an increased risk of developing CD (OR: 1.74) (García Rodríguez et al., 2005). However, most studies showed that smoking status was not associated with surgical requirements (Hoie et al., 2007; Solberg et al., 2014). However, we could not confirm this association in the present study.
Regarding disease location, consistent with a previous study (Ricciuto et al., 2021), isolated colonic disease was associated with fewer surgeries. In our study, the colonic type had a lower surgery risk than the ileo-colonic type (OR: 0.537, 95% CI: 0.342–0.841), and was included in the nomogram as a predictor. For patients with UC, extensive disease is viewed as a risk factor for colectomy. Extensive colonic disease can be considered as a manifestation of severe disease (Hoie et al., 2007; Macaluso et al., 2019). In our study, the long-term efficacy of methotrexate for UC was independent of lesion location. Consistent with a previous study (Peyrin-Biroulet et al., 2010; Thia et al., 2010; Peyrin-Biroulet et al., 2012; Solberg et al., 2014; Yao et al., 2020), perianal involvement and behaviour were included in the nomogram as predictors of the occurrence of surgery. A review of 70 studies concluded that a younger age at diagnosis was associated with a higher risk of colectomy (Macaluso et al., 2019). Further analysis showed that colonic disease accounted for 28.5% (112/393) of patients below 30 years of age and 30.2% (120/398) of patients above 30 years of age. However, we believe that this is not enough to cause the difference and speculate that the risk of surgery is higher in young patients due to their own disease characteristics. Patients who received biologics after methotrexate initiation had a lower risk of surgery (OR: 0.605, 95% CI: 0.430–0.852). This suggests that for patients who cannot be controlled by traditional drugs or who do not respond to drugs, biologic agents should be sought in time to reduce the risk of surgery.

It is noteworthy that the value of surgery for IBD is changing (Buskens and Bemelman, 2019). We need to be aware that surgery should be considered as an alternative treatment rather than a salvage procedure after failed conservative treatment. We hope to use the nomograms to identify the high risk of surgery and administer more aggressive treatments to achieve better outcomes.

Limitations

Our study had some limitations. In our study, the effectiveness of treatment was judged according to patients’ subjective perception and whether there is treatment escalation. There is no standard disease activity score to evaluate the efficacy. Our study was based on IBD BioResource, a United Kingdom hospital-based program, and hence there may be regional limitations and disease severity bias, which may include individuals with more severe disease. Our results are based on a large sample, so we believe that this study is of certain significance.

Conclusion

In conclusion, methotrexate was effective in both, patients with CD and UC, with no significant difference between two groups. Methotrexate is well tolerated by most individuals. Male sex, methotrexate intolerance, and perianal involvement are predictors of early surgery. Treatment in the modern era, colonic and inflammatory diseases, and biological requirements are predictors of low surgery occurrence for CD. Male sex and younger age at diagnosis are predictors of early surgery in patients with UC. The nomograms can predict the 1-, 3- and 5- year risk of surgery for patients with CD and UC, who were initially treated with methotrexate monotherapy, with accuracy and discriminative ability.

Data availability statement

Publicly available datasets were analyzed in this study. This data can be found here: We obtained the data from the United Kingdom IBD BioResource (www.ibdbioresource.nihr.ac.uk), which launched in 2016 as part of the United Kingdom National Institute for Health Research BioResource. To obtain these data, a data application was submitted to IBD BioResource (https://www.ibdbioresource.nihr.ac.uk/index.php/resources/applying-for-access-to-the-ibd-bioresource-panel-2/).

Ethics statement

The studies involving human participants were reviewed and approved by Ethics Committee of Shengjing Hospital affiliated to China Medical University. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin.

Author contributions

MW, LS, and BC contributed to the conception and design of the study, MW and LS contributed to the data collection, statistical analysis, MW, JZ, and HW contributed to manuscript drafting, CZ, LS, and BC contributed to study supervision and critically article revising. All authors contributed to the manuscript writing and approved to the submitted version.

Funding

The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Acknowledgments

We thank NIHR BioResource volunteers for their participation, and gratefully acknowledge NIHR BioResource...
centres, NHS Trusts and staff for their contribution. We thank the National Institute for Health and Care Research, NHS Blood and Transplant, and Health Data Research United Kingdom as part of the Digital Innovation Hub Programme. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

Buknes, C. J., and Bomdel, W. A. (2019). The surgeon and inflammatory bowel disease. Br. J. Surg. 106 (10), 1118–1119. doi:10.1002/bjs.51128
Carbonnel, F., Colombel, J.-F., Filippi, J., Katsanos, K. H., Peyrin-Biroulet, L., Alex, M., et al. (2016). Methotrexate is not superior to placebo for inducing steroid-free remission, but induces steroid-free clinical remission in a larger proportion of patients with ulcerative colitis. Gastroenterology 150 (2), 380–388. e4. doi:10.1053/j.gastro.2015.10.050
Cervoni, J. P., Alby-Leprelle, B., Weil, D., Zhong, P., Aubin, F., Wendling, D., et al. (2020). A pragmatic non-invasive assessment of liver fibrosis in patients with psoriasis, rheumatoid arthritis or Crohn’s disease receiving methotrexate therapy. Clin. Res. Hepatol. Gastroenterol. 445, 100003. doi:10.1016/j.clinre.2020.100003
Charpentier, C., Salleron, J., Savoy, G., Fumery, M., Merle, V., Laberenne, J., et al. (2014). Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. Gut 63 (3), 423–432. doi:10.1136/gutjnl-2012-303664
Coward, S., Clement, F., Benchimol, F. I., Bernstein, C. N., Avina-Zubieta, J. A., Bitton, A., et al. (2019). Past and future burden of inflammatory bowel diseases based on modeling of population-based data. Gastroenterology 156 (5), 1345–1353. e4. doi:10.1053/j.gastro.2019.01.002
Feagan, B. G., Rochon, J., Fedorak, R. N., Irvine, E. J., Wild, G., Sutherland, L., et al. (1995). Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s study group investigators. N. Engl. J. Med. 332 (5), 292–297. doi:10.1056/NEJM19950223320503
Frolkis, A. D., Dykeman, J., Negrón, M. E., Debruyn, J., Jette, N., Fiest, K. M., et al. (2013). Risk of surgery for inflammatory bowel diseases has decreased over time: A systematic review and meta-analysis of population-based studies. Gastroenterology 145 (5), 996–1006. doi:10.1053/j.gastro.2013.07.041
Gabbani, T., Deiana, S., Lunardi, S., Manetti, N., and Annese, V. (2016). Safety of methotrexate in the treatment of Crohn’s disease from Olmsted County, Minnesota (1970-2014). Am. J. Gastroenterol. 107, 1693–1701. doi:10.1038/ajg.2012.298
Peyrin-Biroulet, L., Lotfu, E. V., Jr., Colombel, J. F., and Sandborn, W. J. (2010). The natural history of adult Crohn’s disease in population-based cohorts. Am. J. Gastroenterol. 105, 289–297. doi:10.1038/ajg.2009.579
Raine, T., Bonovas, S., Burisch, J., Kucharzik, T., Adamina, M., Annese, V., et al. (2022). ECCO guidelines on Therapeutics in ulcerative colitis. Medical treatment. J. Crohns Colitis 16 (1), 2–17. doi:10.1093/ecco-jcc/jjab178
Rajitha, P., Biswas, R., Sabitha, M., and Jayakumar, R. (2017). Methotrexate in the treatment of psoriasis and rheumatoid arthritis: Mechanistic insights, current issues and novel delivery approaches. Curr. Pharm. Des. 23 (24), 3550–3566. doi:10.2174/1021661913666150315439
Ran, Z., Wu, K., Matsuoka, K., Ien, Y. T., Wei, S. C., Ahuja, V., et al. (2021). Asian Organization for Crohn’s and Colitis and Asia Pacific Association of Gastroenterology practice recommendations for medical management and monitoring of inflammatory bowel disease in Asia. J. Gastroenterol. Hepatol. 36 (3), 637–645. doi:10.1111/jgh.15185
Riccusto, A., Aardoom, M., Orlanski-Meyer, E., Navon, D., Carman, N., Aloi, M., et al. (2021). Predicting outcomes in pediatric Crohn’s disease for management optimization: Systematic review and consensus statements from the pediatric inflammatory bowel disease-ahead program. Gastroenterology 160 (1), 403–436.e26. e26. doi:10.1053/j.gastro.2020.07.065
Rosen, M. J., Dhawan, A., and Saeed, S. A. (2015). Inflammatory bowel disease in children and adolescents. JAMA Pediatr. 169 (11), 1053–1060. doi:10.1001/jamapediatrics.2015.1982
Sales-Campos, H., Basso, P. J., Alves, V. B., Fonseca, M. T. C., Bondi, G., Nardina, V., et al. (2015). Classical and recent advances in the treatment of inflammatory bowel diseases. Braz J. Med. Biol. Res. 48 (2), 96–107. doi:10.1590/1413-812320143774
Samuel, S., Ingle, S. B., Dhillon, S., Yadav, S., Harmsen, W. S., Zinsmeister, A. R., et al. (2013). Cumulative incidence and risk factors for hospitalization and surgery in a population-based cohort of ulcerative colitis. Inflamm. Bowel Dis. 19 (9), 1858–1866. doi:10.1097/MIB.0b013e31828ce4c5
Samuel, S., Ingle, S. B., Dhillon, S., Yadav, S., Harmsen, W. S., Zinsmeister, A. R., et al. (2014). Long-term cumulative incidence and risk factors for hospitalization and surgery in a population-based cohort of ulcerative colitis. Inflamm. Bowel Dis. 19 (9), 1858–1866. doi:10.1097/MIB.0b013e31828ce4c5

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2022.996065/full#supplementary-material

Wang et al.
Seinen, M. L., Ponsioen, C. Y., de Boer, N. K., Bouma, G., Mulder, C. J. J., et al. (2013). Sustained clinical benefit and tolerability of methotrexate monotherapy after thiopurine therapy in patients with Crohn’s disease. Clin. Gastroenterol. Hepatol. 11 (6), 667–672. doi:10.1016/j.cgh.2012.12.026

Solberg, I. C., Cvančarová, M., Vata, M. H., and Moun, B. (2014). Risk matrix for prediction of advanced disease in a population-based study of patients with Crohn’s Disease (the IBSEN Study). Inflamm. Bowel Dis. 20 (1), 60–68. doi:10.1097/MIB.0000436956.78220.67

Thia, K. T., Sandborn, W. J., Harmsen, W. S., Zinsmeister, A. R., and Loftus, E. V. (2010). Risk factors associated with progression to intestinal complications of Crohn’s disease in a population-based cohort. Gastroenterology 139, 1147–1155. doi:10.1053/j.gastro.2010.06.070

Torres, J., Bonovas, S., Doherty, G., Kucharzik, T., Gisbert, J. P., Raine, T., et al. (2020). ECCO guidelines on Therapeutics in crohn’s disease: Medical treatment. J. Crohns Colitis 14 (1), 4–22. doi:10.1093/jcc/jjz180

Torres, J., Bonovas, S., Doherty, G., Kucharzik, T., Gisbert, J. P., Raine, T., et al. (2020). ECCO guidelines on Therapeutics in crohn’s disease: Medical treatment. J. Crohns Colitis 14 (1), 4–22. doi:10.1093/jcc/jjz180

Tsai, L., Ma, C., Dulai, P. S., Prokop, I. J., Eisenstein, S., Ramamoorthy, S. L., et al. (2021). Contemporary risk of surgery in patients with ulcerative colitis and crohn’s disease: A meta-analysis of population-based cohorts. Clin. Gastroenterol. Hepatol. 19 (10), 2031–2045.e11. e11. doi:10.1016/j.cgh.2020.10.039

Tung, J. P., and Maibach, H. I. (1990). The practical use of methotrexate in psoriasis. Drugs 40 (5), 697–712. doi:10.2165/00003495-199040050-00005

Vasudevan, A., Parthasarathy, N., Con, D., Nicolaides, S., Apostolov, R., Chauhan, A., et al. (2020). Thiopurines vs methotrexate: Comparing tolerability and discontinuation rates in the treatment of inflammatory bowel disease. Aliment. Pharmacol. Ther. 52 (7), 1174–1184. doi:10.1111/apt.16039

Wahed, M., Louis-Auguste, J. R., Baxter, L. M., Lindi, J. K., McCartney, S. A., Lindsay, J. O., et al. (2009). Efficacy of methotrexate in Crohn’s disease and ulcerative colitis patients unresponsive or intolerant to azathioprine/mercaptopurine. Aliment. Pharmacol. Ther. 30 (6), 614–620. doi:10.1111/j.1365-2036.2009.04073.x

Yao, J. Y., Jiang, Y., Ke, J., Lu, Y., Hu, I., and Zhi, M. (2020). Development of a prognostic model for one-year surgery risk in crohn’s disease patients: A retrospective study. World J. Gastroenterol. 26 (5), 524–534. doi:10.3748/wjg.v26.i5.524